Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2021 Sep 11:S2152-2650(21)02033-4. doi: 10.1016/j.clml.2021.09.004. Online ahead of print.NO ABSTRACTPMID:34670732 | DOI:10.1016/j.clml.2021.09.004 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 21, 2021 Category: Cancer & Oncology Authors: Tarek H Mouhieddine Julia Hieulle Erin Moshier Shambavi Richard Joshua Richter Hearn Jay Cho Samir Parekh Bart Barlogie Ajai Chari Sundar Jagannath Deepu Madduri Source Type: research

Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2021 Sep 11:S2152-2650(21)02033-4. doi: 10.1016/j.clml.2021.09.004. Online ahead of print.NO ABSTRACTPMID:34670732 | DOI:10.1016/j.clml.2021.09.004 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 21, 2021 Category: Cancer & Oncology Authors: Tarek H Mouhieddine Julia Hieulle Erin Moshier Shambavi Richard Joshua Richter Hearn Jay Cho Samir Parekh Bart Barlogie Ajai Chari Sundar Jagannath Deepu Madduri Source Type: research

Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2021 Sep 11:S2152-2650(21)02033-4. doi: 10.1016/j.clml.2021.09.004. Online ahead of print.NO ABSTRACTPMID:34670732 | DOI:10.1016/j.clml.2021.09.004 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 21, 2021 Category: Cancer & Oncology Authors: Tarek H Mouhieddine Julia Hieulle Erin Moshier Shambavi Richard Joshua Richter Hearn Jay Cho Samir Parekh Bart Barlogie Ajai Chari Sundar Jagannath Deepu Madduri Source Type: research

Refractory DLBCL: Challenges and Treatment
Clin Lymphoma Myeloma Leuk. 2021 Sep 20:S2152-2650(21)02041-3. doi: 10.1016/j.clml.2021.09.011. Online ahead of print.ABSTRACTDespite a greater understanding of pathologic factors that increase the chance for treatment failure, initial therapy of diffuse large B cell lymphoma (DLBCL) has not evolved from R/CHOP. Although it was anticipated that the genetic underpinnings of the cell or origin would dramatically change treatment, thus far, this has not been realized. Similarly, contrary to the situation with Hodgkin lymphoma, meaningful early treatment response assessment with PET-CT has yet to be established in DLBCL. Never...
Source: Clinical Lymphoma and Myeloma - October 20, 2021 Category: Cancer & Oncology Authors: Mendel Goldfinger Dennis L Cooper Source Type: research

Refractory DLBCL: Challenges and Treatment
Clin Lymphoma Myeloma Leuk. 2021 Sep 20:S2152-2650(21)02041-3. doi: 10.1016/j.clml.2021.09.011. Online ahead of print.ABSTRACTDespite a greater understanding of pathologic factors that increase the chance for treatment failure, initial therapy of diffuse large B cell lymphoma (DLBCL) has not evolved from R/CHOP. Although it was anticipated that the genetic underpinnings of the cell or origin would dramatically change treatment, thus far, this has not been realized. Similarly, contrary to the situation with Hodgkin lymphoma, meaningful early treatment response assessment with PET-CT has yet to be established in DLBCL. Never...
Source: Clinical Lymphoma and Myeloma - October 20, 2021 Category: Cancer & Oncology Authors: Mendel Goldfinger Dennis L Cooper Source Type: research

FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia
Clin Lymphoma Myeloma Leuk. 2021 Sep 16:S2152-2650(21)02034-6. doi: 10.1016/j.clml.2021.09.002. Online ahead of print.ABSTRACTAcute myeloid leukemia (AML) is the most common acute leukemia of adults, with a five-year survival that remains poor (approximately 25%). Knowledge and understanding of AML genomics have expanded tremendously over the past decade and are now included in AML prognostication and treatment decisions. FMS-like tyrosine kinase 3 (FLT3) is a Class III receptor tyrosine kinase (RTK) expressed primarily in the cell membranes of early hematopoietic progenitor cells, found in 28% of all patients with AML. FL...
Source: Clinical Lymphoma and Myeloma - October 15, 2021 Category: Cancer & Oncology Authors: Elli D Novatcheva Yasmine Anouty Ila Saunders James K Mangan Aaron M Goodman Source Type: research

FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia
Clin Lymphoma Myeloma Leuk. 2021 Sep 16:S2152-2650(21)02034-6. doi: 10.1016/j.clml.2021.09.002. Online ahead of print.ABSTRACTAcute myeloid leukemia (AML) is the most common acute leukemia of adults, with a five-year survival that remains poor (approximately 25%). Knowledge and understanding of AML genomics have expanded tremendously over the past decade and are now included in AML prognostication and treatment decisions. FMS-like tyrosine kinase 3 (FLT3) is a Class III receptor tyrosine kinase (RTK) expressed primarily in the cell membranes of early hematopoietic progenitor cells, found in 28% of all patients with AML. FL...
Source: Clinical Lymphoma and Myeloma - October 15, 2021 Category: Cancer & Oncology Authors: Elli D Novatcheva Yasmine Anouty Ila Saunders James K Mangan Aaron M Goodman Source Type: research

FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia
Clin Lymphoma Myeloma Leuk. 2021 Sep 16:S2152-2650(21)02034-6. doi: 10.1016/j.clml.2021.09.002. Online ahead of print.ABSTRACTAcute myeloid leukemia (AML) is the most common acute leukemia of adults, with a five-year survival that remains poor (approximately 25%). Knowledge and understanding of AML genomics have expanded tremendously over the past decade and are now included in AML prognostication and treatment decisions. FMS-like tyrosine kinase 3 (FLT3) is a Class III receptor tyrosine kinase (RTK) expressed primarily in the cell membranes of early hematopoietic progenitor cells, found in 28% of all patients with AML. FL...
Source: Clinical Lymphoma and Myeloma - October 15, 2021 Category: Cancer & Oncology Authors: Elli D Novatcheva Yasmine Anouty Ila Saunders James K Mangan Aaron M Goodman Source Type: research

FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia
Clin Lymphoma Myeloma Leuk. 2021 Sep 16:S2152-2650(21)02034-6. doi: 10.1016/j.clml.2021.09.002. Online ahead of print.ABSTRACTAcute myeloid leukemia (AML) is the most common acute leukemia of adults, with a five-year survival that remains poor (approximately 25%). Knowledge and understanding of AML genomics have expanded tremendously over the past decade and are now included in AML prognostication and treatment decisions. FMS-like tyrosine kinase 3 (FLT3) is a Class III receptor tyrosine kinase (RTK) expressed primarily in the cell membranes of early hematopoietic progenitor cells, found in 28% of all patients with AML. FL...
Source: Clinical Lymphoma and Myeloma - October 15, 2021 Category: Cancer & Oncology Authors: Elli D Novatcheva Yasmine Anouty Ila Saunders James K Mangan Aaron M Goodman Source Type: research

Association Of -308G/A, -238G/A TNF-alpha Polymorphisms with Multiple Myeloma Risk and Survival: A Systematic Review and Meta-Analysis
CONCLUSION: This systematic review and meta-analysis did not reveal a significant effect of -308G/A and -238G/A TNF-α polymorphisms upon risk or survival of MM.PMID:34642126 | DOI:10.1016/j.clml.2021.08.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 13, 2021 Category: Cancer & Oncology Authors: Christina M Alymatiri Georgia T Gkegka Maria Gavriatopoulou Evangelos Terpos Meletios A Dimopoulos Theodoros N Sergentanis Theodora Psaltopoulou Source Type: research

Association Of -308G/A, -238G/A TNF-alpha Polymorphisms with Multiple Myeloma Risk and Survival: A Systematic Review and Meta-Analysis
CONCLUSION: This systematic review and meta-analysis did not reveal a significant effect of -308G/A and -238G/A TNF-α polymorphisms upon risk or survival of MM.PMID:34642126 | DOI:10.1016/j.clml.2021.08.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 13, 2021 Category: Cancer & Oncology Authors: Christina M Alymatiri Georgia T Gkegka Maria Gavriatopoulou Evangelos Terpos Meletios A Dimopoulos Theodoros N Sergentanis Theodora Psaltopoulou Source Type: research

The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
CONCLUSION: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice.PMID:34629286 | DOI:10.1016/j.clml.2021.09.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 11, 2021 Category: Cancer & Oncology Authors: Seval Akpinar Mehmet Hilmi Dogu Serhat Celik Omer Ekinci Ipek Yonal Hindilerden Mehmet Sinan Dal Eren Arslan Davulcu Atakan Tekinalp Fehmi Hindilerden Busra Gokce Ozcan Tuba Hacibekiroglu Mehmet Ali Erkurt Metin Bagci Sinem Namdaroglu Gulten Korkmaz Oktay Source Type: research

The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
CONCLUSION: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice.PMID:34629286 | DOI:10.1016/j.clml.2021.09.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 11, 2021 Category: Cancer & Oncology Authors: Seval Akpinar Mehmet Hilmi Dogu Serhat Celik Omer Ekinci Ipek Yonal Hindilerden Mehmet Sinan Dal Eren Arslan Davulcu Atakan Tekinalp Fehmi Hindilerden Busra Gokce Ozcan Tuba Hacibekiroglu Mehmet Ali Erkurt Metin Bagci Sinem Namdaroglu Gulten Korkmaz Oktay Source Type: research

The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
CONCLUSION: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice.PMID:34629286 | DOI:10.1016/j.clml.2021.09.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 11, 2021 Category: Cancer & Oncology Authors: Seval Akpinar Mehmet Hilmi Dogu Serhat Celik Omer Ekinci Ipek Yonal Hindilerden Mehmet Sinan Dal Eren Arslan Davulcu Atakan Tekinalp Fehmi Hindilerden Busra Gokce Ozcan Tuba Hacibekiroglu Mehmet Ali Erkurt Metin Bagci Sinem Namdaroglu Gulten Korkmaz Oktay Source Type: research

Impact of Radiation Therapy After High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Lymphomas: A Single Center Experience
CONCLUSION: Post HDC auto-SCT RT was well tolerated. DLBCL and HL patients with residual disease treated with the RT had similar long-term survival as those who received RT for consolidation. RT failed to improve the poor survival in patients with post-HDC auto-SCT PD.PMID:34627735 | DOI:10.1016/j.clml.2021.09.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 10, 2021 Category: Cancer & Oncology Authors: Asif Husain Osmani Yasser Khafaga Muhammad Shahzad Rauf Irfan Maghfoor Saad Akhtar Source Type: research

New targets for CAR T therapy in hematologic malignancies
Best Pract Res Clin Haematol. 2021 Sep;34(3):101277. doi: 10.1016/j.beha.2021.101277. Epub 2021 Jun 9.ABSTRACTAs we expand our acumen of the intricacies of hematological malignancies at a genetic and cellular level, we have paved the way in advancing novel targeted therapeutic avenues such as chimeric antigen receptor T-cell therapies (CAR T). Engineering cells to target a specific antigen has led to dramatic remission rates in cases of relapsed/refractory non-Hodgkin lymphoma, acute lymphoblastic leukemia as well as multiple myeloma thus far with trials in place to further advance targeted therapies in other hematological...
Source: Clinical Lymphoma and Myeloma - October 9, 2021 Category: Cancer & Oncology Authors: Malvi Savani Olalekan Oluwole Bhagirathbhai Dholaria Source Type: research

Toxicities associated with adoptive cellular therapies
Best Pract Res Clin Haematol. 2021 Sep;34(3):101287. doi: 10.1016/j.beha.2021.101287. Epub 2021 Jul 24.ABSTRACTChimeric antigen receptor (CAR) T cell therapy is an effective strategy for the treatment of relapsed/refractory hematologic malignancies leading to the Food and Drug Administration (FDA) approval of five CAR T cell products. Despite encouraging efficacy, the widespread utilization of CAR T cell therapy is limited by unique immune mediated toxicities, primarily cytokine release syndrome (CRS) and neurologic toxicity. Data regarding late effects and long-term toxicities of CAR T cell therapy is evolving and include...
Source: Clinical Lymphoma and Myeloma - October 9, 2021 Category: Cancer & Oncology Authors: Doris K Hansen Marian Dam Rawan G Faramand Source Type: research

New targets for CAR T therapy in hematologic malignancies
Best Pract Res Clin Haematol. 2021 Sep;34(3):101277. doi: 10.1016/j.beha.2021.101277. Epub 2021 Jun 9.ABSTRACTAs we expand our acumen of the intricacies of hematological malignancies at a genetic and cellular level, we have paved the way in advancing novel targeted therapeutic avenues such as chimeric antigen receptor T-cell therapies (CAR T). Engineering cells to target a specific antigen has led to dramatic remission rates in cases of relapsed/refractory non-Hodgkin lymphoma, acute lymphoblastic leukemia as well as multiple myeloma thus far with trials in place to further advance targeted therapies in other hematological...
Source: Clinical Lymphoma and Myeloma - October 9, 2021 Category: Cancer & Oncology Authors: Malvi Savani Olalekan Oluwole Bhagirathbhai Dholaria Source Type: research

Toxicities associated with adoptive cellular therapies
Best Pract Res Clin Haematol. 2021 Sep;34(3):101287. doi: 10.1016/j.beha.2021.101287. Epub 2021 Jul 24.ABSTRACTChimeric antigen receptor (CAR) T cell therapy is an effective strategy for the treatment of relapsed/refractory hematologic malignancies leading to the Food and Drug Administration (FDA) approval of five CAR T cell products. Despite encouraging efficacy, the widespread utilization of CAR T cell therapy is limited by unique immune mediated toxicities, primarily cytokine release syndrome (CRS) and neurologic toxicity. Data regarding late effects and long-term toxicities of CAR T cell therapy is evolving and include...
Source: Clinical Lymphoma and Myeloma - October 9, 2021 Category: Cancer & Oncology Authors: Doris K Hansen Marian Dam Rawan G Faramand Source Type: research

Epidemiology of Food Insecurity in a Nationally Representative Sample of Lymphoma Patients
CONCLUSION: Food insecurity is common among lymphoma patients. Therefore, oncologists across the country should be aware of the sociodemographic risk factors for food insecurity in order to assist in mediation, maximizing the efficacy of treatments. Research regarding the impact of food insecurity on therapy compliance and patient outcomes is warranted in future studies.PMID:34615618 | DOI:10.1016/j.clml.2021.09.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 7, 2021 Category: Cancer & Oncology Authors: Taral Jella Thomas B Cwalina Mehdi Hamadani Source Type: research

Epidemiology of Food Insecurity in a Nationally Representative Sample of Lymphoma Patients
CONCLUSION: Food insecurity is common among lymphoma patients. Therefore, oncologists across the country should be aware of the sociodemographic risk factors for food insecurity in order to assist in mediation, maximizing the efficacy of treatments. Research regarding the impact of food insecurity on therapy compliance and patient outcomes is warranted in future studies.PMID:34615618 | DOI:10.1016/j.clml.2021.09.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 7, 2021 Category: Cancer & Oncology Authors: Taral Jella Thomas B Cwalina Mehdi Hamadani Source Type: research

Epidemiology of Food Insecurity in a Nationally Representative Sample of Lymphoma Patients
CONCLUSION: Food insecurity is common among lymphoma patients. Therefore, oncologists across the country should be aware of the sociodemographic risk factors for food insecurity in order to assist in mediation, maximizing the efficacy of treatments. Research regarding the impact of food insecurity on therapy compliance and patient outcomes is warranted in future studies.PMID:34615618 | DOI:10.1016/j.clml.2021.09.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 7, 2021 Category: Cancer & Oncology Authors: Taral Jella Thomas B Cwalina Mehdi Hamadani Source Type: research

Harnessing Apoptosis in AML
Clin Lymphoma Myeloma Leuk. 2021 Sep 4:S2152-2650(21)02018-8. doi: 10.1016/j.clml.2021.08.015. Online ahead of print.ABSTRACTThe treatment landscape for acute myeloid leukemia has expanded significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent or low-dose cytarabine was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being in...
Source: Clinical Lymphoma and Myeloma - October 4, 2021 Category: Cancer & Oncology Authors: Kapil Saxena Courtney DiNardo Naval Daver Marina Konopleva Source Type: research

Harnessing Apoptosis in AML
Clin Lymphoma Myeloma Leuk. 2021 Sep 4:S2152-2650(21)02018-8. doi: 10.1016/j.clml.2021.08.015. Online ahead of print.ABSTRACTThe treatment landscape for acute myeloid leukemia has expanded significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent or low-dose cytarabine was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being in...
Source: Clinical Lymphoma and Myeloma - October 4, 2021 Category: Cancer & Oncology Authors: Kapil Saxena Courtney DiNardo Naval Daver Marina Konopleva Source Type: research

Harnessing Apoptosis in AML
Clin Lymphoma Myeloma Leuk. 2021 Sep 4:S2152-2650(21)02018-8. doi: 10.1016/j.clml.2021.08.015. Online ahead of print.ABSTRACTThe treatment landscape for acute myeloid leukemia has expanded significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent or low-dose cytarabine was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being in...
Source: Clinical Lymphoma and Myeloma - October 4, 2021 Category: Cancer & Oncology Authors: Kapil Saxena Courtney DiNardo Naval Daver Marina Konopleva Source Type: research

Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On (18)F-FDG PET/CT at Baseline
CONCLUSION: Presenting FL> 3 on baseline PET/CT represents a high-risk feature in patients with NDMM. Frontline ASCT with HDT prolonged the survival of patients with FL> 3.PMID:34598908 | DOI:10.1016/j.clml.2021.08.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 2, 2021 Category: Cancer & Oncology Authors: Hee Jeong Cho Dong Won Baek Ju-Hyung Kim Jungmin Lee Yu Kyung Chung Sung-Hoon Jung Ga-Young Song Seo-Yeon Ahn Jae-Sook Ahn Deok-Hwan Yang Je-Jung Lee Hyeoung-Joon Kim Chae Moon Hong Shin Young Jeong Jung-Joon Min Sang-Kyun Sohn Joon Ho Moon Source Type: research

The Impact of Atrial Fibrillation on hospitalization Outcomes for Patients With Chronic Lymphocytic Leukemia Using the National Inpatient Sample Database
Clin Lymphoma Myeloma Leuk. 2021 Aug 28:S2152-2650(21)00364-5. doi: 10.1016/j.clml.2021.08.006. Online ahead of print.ABSTRACTBACKGROUND: The incidence of atrial fibrillation (AF) in patients with chronic lymphocytic leukemia (CLL) has been on the rise. However, the excess burden added by AF to the morbidity and mortality of CLL patients especially in the hospitalized setting is undetermined.METHODS: The National Inpatient Sample (NIS) database was accessed to gather data of hospitalized CLL patients with AF from 2009 to 2018. Propensity-score matching (PSM) and logistic regression model were performed to control for basel...
Source: Clinical Lymphoma and Myeloma - October 2, 2021 Category: Cancer & Oncology Authors: Mohammad Ammad Ud Din Samarthkumar Thakkar Harsh Patel Hassan Saeed Syed Ather Hussain Hania Liaqat Aneeqa Zafar Sourbha S Dani Sarju Ganatra Faiz Anwer Source Type: research

Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On (18)F-FDG PET/CT at Baseline
CONCLUSION: Presenting FL> 3 on baseline PET/CT represents a high-risk feature in patients with NDMM. Frontline ASCT with HDT prolonged the survival of patients with FL> 3.PMID:34598908 | DOI:10.1016/j.clml.2021.08.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 2, 2021 Category: Cancer & Oncology Authors: Hee Jeong Cho Dong Won Baek Ju-Hyung Kim Jungmin Lee Yu Kyung Chung Sung-Hoon Jung Ga-Young Song Seo-Yeon Ahn Jae-Sook Ahn Deok-Hwan Yang Je-Jung Lee Hyeoung-Joon Kim Chae Moon Hong Shin Young Jeong Jung-Joon Min Sang-Kyun Sohn Joon Ho Moon Source Type: research

The Impact of Atrial Fibrillation on hospitalization Outcomes for Patients With Chronic Lymphocytic Leukemia Using the National Inpatient Sample Database
Clin Lymphoma Myeloma Leuk. 2021 Aug 28:S2152-2650(21)00364-5. doi: 10.1016/j.clml.2021.08.006. Online ahead of print.ABSTRACTBACKGROUND: The incidence of atrial fibrillation (AF) in patients with chronic lymphocytic leukemia (CLL) has been on the rise. However, the excess burden added by AF to the morbidity and mortality of CLL patients especially in the hospitalized setting is undetermined.METHODS: The National Inpatient Sample (NIS) database was accessed to gather data of hospitalized CLL patients with AF from 2009 to 2018. Propensity-score matching (PSM) and logistic regression model were performed to control for basel...
Source: Clinical Lymphoma and Myeloma - October 2, 2021 Category: Cancer & Oncology Authors: Mohammad Ammad Ud Din Samarthkumar Thakkar Harsh Patel Hassan Saeed Syed Ather Hussain Hania Liaqat Aneeqa Zafar Sourbha S Dani Sarju Ganatra Faiz Anwer Source Type: research

Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma
Clin Lymphoma Myeloma Leuk. 2021 Aug 31:S2152-2650(21)02016-4. doi: 10.1016/j.clml.2021.08.011. Online ahead of print.ABSTRACTGerminal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) at diagnosis is associated with superior long-term outcomes compared to non-GCB-DLBCL in patients treated with conventional chemo-immunotherapy. Whether cell of origin (COO) by Hans algorithm retains its prognostic significance in patients with (R/R) relapsed/refractory DLBCL undergoing autologous hematopoietic cell transplant (auto-HCT) is not well established. Three hundred and fifty-seven patients underwent auto-HCT between 200...
Source: Clinical Lymphoma and Myeloma - October 1, 2021 Category: Cancer & Oncology Authors: Madiha Iqbal Yennifer Gil Castano Jonas Paludo Allison Rosenthal Zhuo Li Manuel Beltran Muhamad Alhaj Moustafa David Inwards Luis Porrata Ivana Micallef Jose C Villasboas Bisneto Patrick Johnston Stephen M Ansell Craig Reeder Hemant Murthy Vivek Roy James Source Type: research

Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy
Clin Lymphoma Myeloma Leuk. 2021 Sep 9:S2152-2650(21)02017-6. doi: 10.1016/j.clml.2021.08.014. Online ahead of print.ABSTRACTBACKGROUND: Achievement of initial remission remains the most important clinical factor predicting long term survival in acute myeloid leukemia (AML) patients treated with intensive chemotherapy. Yet, whether the patient subset in need of a second cycle of intensive induction chemotherapy to reach remission experiences inferior outcomes compared to patients reaching remission after a single cycle of therapy, remains uncertain.PATIENTS AND METHODS: Retrospective analysis of 302 consecutive AML patient...
Source: Clinical Lymphoma and Myeloma - October 1, 2021 Category: Cancer & Oncology Authors: Gal Sharvit Gabriel Heering Maya Zlotnik Drorit Merkel Arnon Nagler Abraham Avigdor Avichai Shimoni Jonathan Canaani Source Type: research

Diabetes and the Prognosis in Patients With Non-Hodgkin Lymphoma: A Meta-analysis of Cohort Studies
Clin Lymphoma Myeloma Leuk. 2021 Aug 31:S2152-2650(21)02015-2. doi: 10.1016/j.clml.2021.08.013. Online ahead of print.ABSTRACTBACKGROUND: Consensus lacks regarding the association between diabetes mellitus (DM) and the prognosis of patients with non-Hodgkin lymphoma (NHL). We aimed to systematically evaluate the above association, as well as the potential influence of metformin use in a meta-analysis of cohort studies.MATERIALS AND METHODS: Cohort studies investigating the association between DM and survival outcomes of patients with NHL were included by search of electronic databases that included PubMed, Embase, and Web ...
Source: Clinical Lymphoma and Myeloma - October 1, 2021 Category: Cancer & Oncology Authors: Zhen Han Hong Xu Meiqing Zhao Fanjing Jing Hongwei Xue Shuxin Xiao Source Type: research

Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma
Clin Lymphoma Myeloma Leuk. 2021 Aug 31:S2152-2650(21)02016-4. doi: 10.1016/j.clml.2021.08.011. Online ahead of print.ABSTRACTGerminal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) at diagnosis is associated with superior long-term outcomes compared to non-GCB-DLBCL in patients treated with conventional chemo-immunotherapy. Whether cell of origin (COO) by Hans algorithm retains its prognostic significance in patients with (R/R) relapsed/refractory DLBCL undergoing autologous hematopoietic cell transplant (auto-HCT) is not well established. Three hundred and fifty-seven patients underwent auto-HCT between 200...
Source: Clinical Lymphoma and Myeloma - October 1, 2021 Category: Cancer & Oncology Authors: Madiha Iqbal Yennifer Gil Castano Jonas Paludo Allison Rosenthal Zhuo Li Manuel Beltran Muhamad Alhaj Moustafa David Inwards Luis Porrata Ivana Micallef Jose C Villasboas Bisneto Patrick Johnston Stephen M Ansell Craig Reeder Hemant Murthy Vivek Roy James Source Type: research

Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy
Clin Lymphoma Myeloma Leuk. 2021 Sep 9:S2152-2650(21)02017-6. doi: 10.1016/j.clml.2021.08.014. Online ahead of print.ABSTRACTBACKGROUND: Achievement of initial remission remains the most important clinical factor predicting long term survival in acute myeloid leukemia (AML) patients treated with intensive chemotherapy. Yet, whether the patient subset in need of a second cycle of intensive induction chemotherapy to reach remission experiences inferior outcomes compared to patients reaching remission after a single cycle of therapy, remains uncertain.PATIENTS AND METHODS: Retrospective analysis of 302 consecutive AML patient...
Source: Clinical Lymphoma and Myeloma - October 1, 2021 Category: Cancer & Oncology Authors: Gal Sharvit Gabriel Heering Maya Zlotnik Drorit Merkel Arnon Nagler Abraham Avigdor Avichai Shimoni Jonathan Canaani Source Type: research

Diabetes and the Prognosis in Patients With Non-Hodgkin Lymphoma: A Meta-analysis of Cohort Studies
Clin Lymphoma Myeloma Leuk. 2021 Aug 31:S2152-2650(21)02015-2. doi: 10.1016/j.clml.2021.08.013. Online ahead of print.ABSTRACTBACKGROUND: Consensus lacks regarding the association between diabetes mellitus (DM) and the prognosis of patients with non-Hodgkin lymphoma (NHL). We aimed to systematically evaluate the above association, as well as the potential influence of metformin use in a meta-analysis of cohort studies.MATERIALS AND METHODS: Cohort studies investigating the association between DM and survival outcomes of patients with NHL were included by search of electronic databases that included PubMed, Embase, and Web ...
Source: Clinical Lymphoma and Myeloma - October 1, 2021 Category: Cancer & Oncology Authors: Zhen Han Hong Xu Meiqing Zhao Fanjing Jing Hongwei Xue Shuxin Xiao Source Type: research

Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry
CONCLUSIONS: Acknowledging observational study and inferential limitations, this exploratory analysis of a predominantly community-based population suggests that t (11;14) is a neutral prognostic factor in the general MM population but may be a negative factor for overall survival in AA patients.PMID:34588149 | DOI:10.1016/j.clml.2021.08.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 30, 2021 Category: Cancer & Oncology Authors: Cristina Gasparetto Sundar Jagannath Robert M Rifkin Brian G M Durie Mohit Narang Howard R Terebelo Kathleen Toomey James W Hardin Lynne Wagner Sikander Ailawadhi James L Omel Shankar Srinivasan Mazaher Dhalla Donna Catamero Amani Kitali Amit Agarwal Rafa Source Type: research

Two-Stage Approaches to Accounting for Patient Heterogeneity in Machine Learning Risk Prediction Models in Oncology
CONCLUSION: Our two-stage modeling approach that accounts for cancer type-specific risk heterogeneity has improved calibration and discrimination than a model agnostic to cancer types.PMID:34591602 | DOI:10.1200/CCI.21.00077 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 30, 2021 Category: Cancer & Oncology Authors: Eun Jeong Oh Ravi B Parikh Corey Chivers Jinbo Chen Source Type: research

Follicular Lymphoma: Refining Prognostic Models and Impact of Pod-24 in Clinical Outcomes
Clin Lymphoma Myeloma Leuk. 2021 Aug 27:S2152-2650(21)00363-3. doi: 10.1016/j.clml.2021.08.004. Online ahead of print.ABSTRACTFollicular lymphoma (FL) is the most common indolent lymphoma, accounting for 20%-25% of all non-Hodgkin's lymphomas (NHLs). It is a malignancy with variable biologic presentation and heterogeneous clinical outcomes. Several models incorporating clinical laboratory variables and molecular biomarkers are able to predict its prognosis, allowing to stratify patients into different risk groups. However, these prognostic scores should not be used to indicate first-line treatment or risk-adapted therapeut...
Source: Clinical Lymphoma and Myeloma - September 28, 2021 Category: Cancer & Oncology Authors: Daniel Silva Nogueira Lu ís Alberto de Pádua Covas Lage Hebert Fabr ício Culler Juliana Pereira Source Type: research

Follicular Lymphoma: Refining Prognostic Models and Impact of Pod-24 in Clinical Outcomes
Clin Lymphoma Myeloma Leuk. 2021 Aug 27:S2152-2650(21)00363-3. doi: 10.1016/j.clml.2021.08.004. Online ahead of print.ABSTRACTFollicular lymphoma (FL) is the most common indolent lymphoma, accounting for 20%-25% of all non-Hodgkin's lymphomas (NHLs). It is a malignancy with variable biologic presentation and heterogeneous clinical outcomes. Several models incorporating clinical laboratory variables and molecular biomarkers are able to predict its prognosis, allowing to stratify patients into different risk groups. However, these prognostic scores should not be used to indicate first-line treatment or risk-adapted therapeut...
Source: Clinical Lymphoma and Myeloma - September 28, 2021 Category: Cancer & Oncology Authors: Daniel Silva Nogueira Lu ís Alberto de Pádua Covas Lage Hebert Fabr ício Culler Juliana Pereira Source Type: research

Follicular Lymphoma: Refining Prognostic Models and Impact of Pod-24 in Clinical Outcomes
Clin Lymphoma Myeloma Leuk. 2021 Aug 27:S2152-2650(21)00363-3. doi: 10.1016/j.clml.2021.08.004. Online ahead of print.ABSTRACTFollicular lymphoma (FL) is the most common indolent lymphoma, accounting for 20%-25% of all non-Hodgkin's lymphomas (NHLs). It is a malignancy with variable biologic presentation and heterogeneous clinical outcomes. Several models incorporating clinical laboratory variables and molecular biomarkers are able to predict its prognosis, allowing to stratify patients into different risk groups. However, these prognostic scores should not be used to indicate first-line treatment or risk-adapted therapeut...
Source: Clinical Lymphoma and Myeloma - September 28, 2021 Category: Cancer & Oncology Authors: Daniel Silva Nogueira Lu ís Alberto de Pádua Covas Lage Hebert Fabr ício Culler Juliana Pereira Source Type: research

Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies
Clin Lymphoma Myeloma Leuk. 2021 Aug 28:S2152-2650(21)02012-7. doi: 10.1016/j.clml.2021.08.009. Online ahead of print.ABSTRACTINTRODUCTION: Tumor lysis syndrome (TLS) is a commonly observed oncological emergency that requires prompt diagnosis and treatment. Rasburicase is a recombinant urate oxidase endorsed in TLS for the treatment of hyperuricemia. The effect of single-dose 7.5 mg rasburicase at longer follow-ups was not widely investigated.PATIENTS AND METHODS: Eighty-two patients included in the study with clinical TLS and laboratory TLS. The primary endpoint was the normalization of uric acid (
Source: Clinical Lymphoma and Myeloma - September 27, 2021 Category: Cancer & Oncology Authors: Samet Yaman Semih Ba şcı G ökhan Turan Bahar Uncu Ulu Tu ğçe Nur Yiğenoğlu Mehmet Sinan Dal Merih K ızıl Çakar Fevzi Altunta ş Source Type: research

Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies
Clin Lymphoma Myeloma Leuk. 2021 Aug 28:S2152-2650(21)02012-7. doi: 10.1016/j.clml.2021.08.009. Online ahead of print.ABSTRACTINTRODUCTION: Tumor lysis syndrome (TLS) is a commonly observed oncological emergency that requires prompt diagnosis and treatment. Rasburicase is a recombinant urate oxidase endorsed in TLS for the treatment of hyperuricemia. The effect of single-dose 7.5 mg rasburicase at longer follow-ups was not widely investigated.PATIENTS AND METHODS: Eighty-two patients included in the study with clinical TLS and laboratory TLS. The primary endpoint was the normalization of uric acid (
Source: Clinical Lymphoma and Myeloma - September 27, 2021 Category: Cancer & Oncology Authors: Samet Yaman Semih Ba şcı G ökhan Turan Bahar Uncu Ulu Tu ğçe Nur Yiğenoğlu Mehmet Sinan Dal Merih K ızıl Çakar Fevzi Altunta ş Source Type: research

SOHO State of the Art Updates & amp; Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Clin Lymphoma Myeloma Leuk. 2021 Aug 20:S2152-2650(21)00361-X. doi: 10.1016/j.clml.2021.08.003. Online ahead of print.ABSTRACTPhiladelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) was historically considered to be a very poor-risk subtype of ALL. However, with the introduction of highly potent BCR-ABL tyrosine kinase inhibitors (TKIs), Ph+ ALL can now be considered relatively favorable-risk acute leukemia. Considering the high rates of measurable residual disease negativity and excellent long-term survival that has been achieved with regimens incorporating later-generation TKIs and particularly with ponat...
Source: Clinical Lymphoma and Myeloma - September 25, 2021 Category: Cancer & Oncology Authors: Nicholas J Short Hagop Kantarjian Elias Jabbour Source Type: research

SOHO State of the Art Updates & amp; Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Clin Lymphoma Myeloma Leuk. 2021 Aug 20:S2152-2650(21)00361-X. doi: 10.1016/j.clml.2021.08.003. Online ahead of print.ABSTRACTPhiladelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) was historically considered to be a very poor-risk subtype of ALL. However, with the introduction of highly potent BCR-ABL tyrosine kinase inhibitors (TKIs), Ph+ ALL can now be considered relatively favorable-risk acute leukemia. Considering the high rates of measurable residual disease negativity and excellent long-term survival that has been achieved with regimens incorporating later-generation TKIs and particularly with ponat...
Source: Clinical Lymphoma and Myeloma - September 25, 2021 Category: Cancer & Oncology Authors: Nicholas J Short Hagop Kantarjian Elias Jabbour Source Type: research

Efficacy of peripheral arterial access for peripheral blood stem cells collection
J Clin Apher. 2021 Sep 24. doi: 10.1002/jca.21940. Online ahead of print.ABSTRACTBACKGROUND: Transplantation of peripheral blood stem cells (PBSCs) mobilized by cytokines is increasingly applied to treat patients with hematologic diseases, such as lymphoma, multiple myeloma, leukemia, etc. Successful hematopoietic stem cell transplantation (HSCT) increasingly depends on the collection of hematopoietic stem cells (HSCs) from peripheral blood. Peripheral vein (PV) is the most common type of blood access. When the blood vessels are not well filled and the blood flow is insufficient, the machine will appear repeated low pressu...
Source: Clinical Lymphoma and Myeloma - September 24, 2021 Category: Cancer & Oncology Authors: Min Tian Xiangmin Li Feng Liu Dongmei Xu Lanlan Sun Qiuhuan Li Yue Ling Yingxue Bai Xiaoling Wu Yun Liu Jianhong Qiao Source Type: research

Efficacy of peripheral arterial access for peripheral blood stem cells collection
J Clin Apher. 2021 Sep 24. doi: 10.1002/jca.21940. Online ahead of print.ABSTRACTBACKGROUND: Transplantation of peripheral blood stem cells (PBSCs) mobilized by cytokines is increasingly applied to treat patients with hematologic diseases, such as lymphoma, multiple myeloma, leukemia, etc. Successful hematopoietic stem cell transplantation (HSCT) increasingly depends on the collection of hematopoietic stem cells (HSCs) from peripheral blood. Peripheral vein (PV) is the most common type of blood access. When the blood vessels are not well filled and the blood flow is insufficient, the machine will appear repeated low pressu...
Source: Clinical Lymphoma and Myeloma - September 24, 2021 Category: Cancer & Oncology Authors: Min Tian Xiangmin Li Feng Liu Dongmei Xu Lanlan Sun Qiuhuan Li Yue Ling Yingxue Bai Xiaoling Wu Yun Liu Jianhong Qiao Source Type: research

A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
CONCLUSIONS: Given the limited enrollment, no clear safety or efficacy conclusions about VenPd can be drawn. Preliminary safety data, particularly the occurrence of cytopenias, can be used to guide dosing strategies for future combinations of venetoclax with immunomodulatory agents.PMID:34551886 | DOI:10.1016/j.clml.2021.07.029 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 23, 2021 Category: Cancer & Oncology Authors: Cristina Gasparetto Kristian M Bowles Al-Ola Abdallah Lura Morris Gudrun Mander Sheryl Coppola Jing Wang Jeremy A Ross Orlando F Bueno Emma Arriola Maria Victoria Mateos Source Type: research

Myelodysplastic Syndromes: A New Decade
Clin Lymphoma Myeloma Leuk. 2021 Aug 2:S2152-2650(21)00315-3. doi: 10.1016/j.clml.2021.07.031. Online ahead of print.ABSTRACTMyelodysplastic syndromes (MDS) are a group of heterogeneous clonal hematopoietic stem cell disorders. The 2020 Surveillance, Epidemiology, and End Results data demonstrates the incidence rate of MDS increases with age especially in those greater than 70 years of age. Risk stratification that impact prognosis, survival, and rate of acute myeloid leukemia (AML) transformation in MDS is largely dependent on revised International Prognostic Scoring System along with molecular genetic testing as a supple...
Source: Clinical Lymphoma and Myeloma - September 21, 2021 Category: Cancer & Oncology Authors: Virginia O Volpe Guillermo Garcia-Manero Rami S Komrokji Source Type: research

Myelodysplastic Syndromes: A New Decade
Clin Lymphoma Myeloma Leuk. 2021 Aug 2:S2152-2650(21)00315-3. doi: 10.1016/j.clml.2021.07.031. Online ahead of print.ABSTRACTMyelodysplastic syndromes (MDS) are a group of heterogeneous clonal hematopoietic stem cell disorders. The 2020 Surveillance, Epidemiology, and End Results data demonstrates the incidence rate of MDS increases with age especially in those greater than 70 years of age. Risk stratification that impact prognosis, survival, and rate of acute myeloid leukemia (AML) transformation in MDS is largely dependent on revised International Prognostic Scoring System along with molecular genetic testing as a supple...
Source: Clinical Lymphoma and Myeloma - September 21, 2021 Category: Cancer & Oncology Authors: Virginia O Volpe Guillermo Garcia-Manero Rami S Komrokji Source Type: research

Myelodysplastic Syndromes: A New Decade
Clin Lymphoma Myeloma Leuk. 2021 Aug 2:S2152-2650(21)00315-3. doi: 10.1016/j.clml.2021.07.031. Online ahead of print.ABSTRACTMyelodysplastic syndromes (MDS) are a group of heterogeneous clonal hematopoietic stem cell disorders. The 2020 Surveillance, Epidemiology, and End Results data demonstrates the incidence rate of MDS increases with age especially in those greater than 70 years of age. Risk stratification that impact prognosis, survival, and rate of acute myeloid leukemia (AML) transformation in MDS is largely dependent on revised International Prognostic Scoring System along with molecular genetic testing as a supple...
Source: Clinical Lymphoma and Myeloma - September 21, 2021 Category: Cancer & Oncology Authors: Virginia O Volpe Guillermo Garcia-Manero Rami S Komrokji Source Type: research